慢性炎症性脱髄性多発神経炎の世界市場：流通チャネル・投与経路・地域別の分析・予測 (2025-2035年)

慢性炎症性脱髄性多発神経炎の市場の主な成長要因のひとつは、革新的かつ効果的な治療法に対する需要の高まりです。

慢性炎症性脱髄性多発神経炎に関する認知が医療従事者および患者の間で広まる中、疾患の診断率も大きく上昇しており、それに伴ってより高度な治療法を求めるニーズも増加しています。従来の治療法である静注免疫グロブリン療法 (IVIG) や血漿交換療法がすべての患者に有効とは限らないことから、標的型の生物学的製剤や経口免疫抑制薬といった新しい治療選択肢の登場が、より個別化された効果的なケアの実現に貢献しています。

さらに、慢性炎症性脱髄性多発神経炎の認知度向上、診断技術の進歩、および世界的な自己免疫疾患の増加も、患者数の拡大につながっています。より多くの患者が早期に診断されるようになることで、より迅速かつ持続的な症状緩和をもたらす治療法へのニーズが高まり、市場の成長を後押ししています。特に、VyvgartなどのFcRn阻害薬など、新しい生物学的製剤の開発は、免疫介在性メカニズムに直接作用し、治療効果の向上や副作用の軽減にもつながっています。

全体として、治療の高度化と患者アウトカムの改善への注力が、慢性炎症性脱髄性多発神経炎市場を成長へと導く重要な要因となっています。

一方で、市場にはいくつかの課題も依然として存在し、市場の拡大を妨げています。まず大きな障壁となっているのが、治療費の高さです。IVIG、血漿交換、生物学的製剤といった治療法は非常に高額であり、慢性炎症性脱髄性多発神経炎は長期的かつ継続的な管理が必要とされる疾患であるため、頻回な治療による経済的負担が患者および医療制度の双方に重くのしかかっています。さらに、FcRn阻害薬などの新規バイオ医薬品の価格の高さも、この問題を一層深刻にしており、特に医療資源の限られた地域においては治療へのアクセスが困難な状況です。

もう一つの重要な課題は、慢性炎症性脱髄性多発神経炎はまれな疾患であり、ギランバレー症候群 (GBS) など他の神経疾患との症状の重複があるため、誤診や診断の遅延が頻繁に発生します。こうした遅れにより、神経障害が進行した段階での診断となるケースも多く、治療の効果が限定的になる場合があります。

さらに、新たな治療法の開発が進んでいるとはいえ、難治性など特定のサブタイプに対する治療選択肢が依然として乏しいことも大きな課題です。IVIGや血漿交換などの第一選択治療に反応しない患者に対して、有効な第二選択治療が見つかっていないことは、今なお大きなアンメットニーズとなっています。

最後に、最後に、ステロイドやIVIGといった従来治療による副作用も一部の患者にとって問題となっており、長期治療の継続が困難になる要因となっています。そのため、効果がありながら副作用の少ない治療法を見出すことが、同市場における今後の重要課題のひとつであると言えるでしょう。

当レポートでは、世界の慢性炎症性脱髄性多発神経炎の市場を調査し、主要動向、市場影響因子の分析、法規制環境、技術・特許の分析、臨床試験の動向、市場規模の推移・予測、各種区分・地域/主要国別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

エグゼクティブサマリー

第1章 世界の慢性炎症性脱髄性多発神経炎市場：業界展望

• 市場動向
• 規制の枠組み
• 疫学分析
• 臨床試験分析
• 市場力学
  • 影響分析
  • 市場促進要因
  • 市場の課題
  • 市場機会

第2章 世界の慢性炎症性脱髄性多発神経炎市場：流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第3章 慢性炎症性脱髄性多発神経炎の世界市場：投与経路別

• 静脈内
• 経口
• その他

第4章 世界の慢性炎症性脱髄性多発神経炎市場：地域別

• 北米
  • 主な調査結果
  • 市場力学
  • 市場規模・予測
• 欧州
  • 主な調査結果
  • 市場力学
  • 市場規模・予測
• アジア太平洋
  • 主な調査結果
  • 市場力学
  • 市場規模・予測
• 世界のその他の地域
  • 主な調査結果
  • 市場力学
  • 市場規模・予測

第5章 世界の慢性炎症性脱髄性多発神経炎市場：競合情勢と企業プロファイル

• 主要戦略と開発
  • M&A
  • 相乗効果のある活動
  • 事業拡大と資金調達
  • 製品の発売と承認
  • その他の活動
• 企業プロファイル
  • Sanofi
  • Grifols, S.A.
  • Kedrion Biopharma Inc.
  • Octapharma AG
  • AstraZeneca s (Alexion Pharmaceuticals, Inc.)
  • Argenx SE
  • Amgen (Horizon Therapeutics plc)
  • Biogen Inc.
  • GlaxoSmithKline (Human Genome Sciences, Inc.)
  • Pfizer Inc.
  • Takeda Pharmaceutical Company

第6章 調査手法

List of Figures

Figure Global Chronic Inflammatory Demyelinating Polyneuropathy Market (by Region), $Billion, 2024 and 2035

Figure Global Chronic Inflammatory Demyelinating Polyneuropathy Market Key Trends, Analysis

List of Tables

• Table Global Chronic Inflammatory Demyelinating Polyneuropathy Market Dynamics, Impact Analysis
• Table Global Chronic Inflammatory Demyelinating Polyneuropathy Market (by Distribution Channel), $Billion, 2024-2035
• Table Global Chronic Inflammatory Demyelinating Polyneuropathy Market (by Route of Administration), $Billion, 2024-2035
• Table Global Chronic Inflammatory Demyelinating Polyneuropathy Market (by Region), $Billion, 2024-2035

Global Chronic Inflammatory Demyelinating Polyneuropathy Market, Analysis and Forecast: 2025-2035

Chronic inflammatory demyelinating polyneuropathy is a rare autoimmune disorder that primarily affects the peripheral nervous system. It is characterized by inflammation and demyelination (damage to the protective covering of nerves) of the nerve fibers, which leads to muscle weakness, sensory disturbances, and reduced reflexes. Chronic inflammatory demyelinating polyneuropathy is considered the chronic counterpart of Guillain-Barre syndrome (GBS), although chronic inflammatory demyelinating polyneuropathy tends to progress more slowly and is often recurrent.

Chronic inflammatory demyelinating polyneuropathy occurs when the body's immune system mistakenly attacks the myelin sheath, which insulates nerve fibers and allows for efficient nerve signal transmission. As a result, nerve conduction becomes impaired, leading to symptoms such as numbness, tingling, weakness, and pain in the limbs. Over time, if left untreated, Chronic inflammatory demyelinating polyneuropathy can cause permanent nerve damage and disability.

The disease can affect individuals of any age but is most commonly diagnosed in adults between the ages of 40 and 60. The cause of Chronic inflammatory demyelinating polyneuropathy is not fully understood, but it is thought to involve genetic predisposition and environmental factors that trigger an immune response. Chronic inflammatory demyelinating polyneuropathy is often treated with therapies that modify the immune system, such as intravenous immunoglobulin (IVIG), plasma exchange, and immunosuppressive drugs.

Early diagnosis and treatment are crucial for preventing long-term disability and improving the patient's quality of life. With proper management, many individuals with Chronic inflammatory demyelinating polyneuropathy can experience symptom relief and regain lost functionality.

One of the key drivers of the Chronic Inflammatory Demyelinating Polyneuropathy market is the growing demand for innovative and effective treatments. As awareness of Chronic inflammatory demyelinating polyneuropathy increases, both among healthcare providers and patients, there is a significant rise in the diagnosis rate of the disease. This, in turn, is driving the demand for more advanced therapies to manage the condition, especially as traditional treatments like IVIG (intravenous immunoglobulin) and plasma exchange may not be effective for all patients. The introduction of targeted biologic therapies and oral immunosuppressive treatments has opened up new treatment avenues, providing more personalized and effective care options for Chronic inflammatory demyelinating polyneuropathy patients.

Additionally, the increased awareness of Chronic inflammatory demyelinating polyneuropathy, improved diagnostic capabilities, and the growing prevalence of autoimmune diseases globally are contributing to the expanding patient pool. As more patients are diagnosed early, the need for innovative therapies that can offer faster, more sustained relief from symptoms is driving market growth. Furthermore, the development of new biologic therapies like FcRn inhibitors (e.g., Vyvgart) is addressing the immune-mediated mechanisms at the core of Chronic inflammatory demyelinating polyneuropathy, leading to better patient outcomes and fewer side effects.

Overall, the focus on advancing treatment options and improving patient outcomes is a key factor driving the growth of the Chronic inflammatory demyelinating polyneuropathy market.

Despite the growth of the Chronic Inflammatory Demyelinating Polyneuropathy market, several challenges continue to hinder its progress. One of the primary obstacles is the high cost of treatment, particularly for therapies such as intravenous immunoglobulin (IVIG), plasma exchange, and biologic therapies. These treatments can be expensive, especially considering that Chronic inflammatory demyelinating polyneuropathy often requires long-term management with frequent administration, leading to significant financial burden for both patients and healthcare systems. In addition, the high cost of novel biologic treatments, such as FcRn inhibitors, further compounds this challenge, limiting accessibility, particularly in regions with limited healthcare resources.

Another key challenge is the underdiagnosis and misdiagnosis of Chronic inflammatory demyelinating polyneuropathy. Given its rare nature and the overlap of symptoms with other neurological disorders like Guillain-Barre syndrome (GBS), Chronic inflammatory demyelinating polyneuropathy is often misdiagnosed or diagnosed at later stages when nerve damage has already occurred. This delay in diagnosis can lead to worsened patient outcomes and a lack of timely intervention, affecting the effectiveness of treatment.

Additionally, while there has been significant progress in the development of new therapies, the lack of treatment options for specific subtypes of Chronic inflammatory demyelinating polyneuropathy, such as refractory Chronic inflammatory demyelinating polyneuropathy, remains a major hurdle. Some patients do not respond adequately to first-line therapies like IVIG or plasma exchange, and finding effective second-line treatments for these patients remains an area of unmet need.

Finally, side effects from traditional treatments like steroids and IVIG can be problematic for some patients, limiting their ability to adhere to long-term treatment regimens. As a result, finding therapies that are both effective and have fewer side effects remains a critical challenge in the Chronic inflammatory demyelinating polyneuropathy market.

In conclusion, while the chronic inflammatory demyelinating polyneuropathy market is experiencing growth, costly treatments, diagnostic challenges, limited treatment options for refractory cases, and side effects continue to present barriers that need to be addressed to fully realize the potential of Chronic inflammatory demyelinating polyneuropathy market.

The global Chronic Inflammatory Demyelinating Polyneuropathy market is highly competitive, with several key players driving innovation and market growth. Leading companies such as Grifols, Kedrion Biopharma, Octapharma, Alexion Pharmaceuticals (now part of AstraZeneca), Argenx, Horizon Therapeutics (acquired by Amgen), and Biogen are at the forefront of providing treatments for chronic inflammatory demyelinating polyneuropathy. These companies are heavily involved in the development of intravenous immunoglobulin (IVIG) therapies, which are the mainstay of chronic inflammatory demyelinating polyneuropathy treatment. In addition, Argenx has introduced Vyvgart (efgartigimod), a FcRn inhibitor, which has shown promise in treating chronic inflammatory demyelinating polyneuropathy by modulating the immune system and reducing autoantibody activity.

As the market for chronic inflammatory demyelinating polyneuropathy treatments expands, these companies are also investing in new, innovative therapies that go beyond traditional immunoglobulin treatments. Biogen and Horizon Therapeutics, for example, are exploring biologic therapies and immune modulators, which can offer more targeted treatments for patients with chronic inflammatory demyelinating polyneuropathy. The competition is also driven by the increasing demand for personalized treatments and more effective solutions that can provide long-term relief, as current therapies often involve regular infusions and do not cure the disease.

These leading companies are contributing to the growing range of treatment options for chronic inflammatory demyelinating polyneuropathy, ultimately improving patient outcomes and quality of life. As the disease remains underdiagnosed in many cases, the focus on early diagnosis and innovative treatments is expected to drive further growth in the chronic inflammatory demyelinating polyneuropathy market.

Chronic Inflammatory Demyelinating Polyneuropathy Market Segmentation:

Segmentation 1: by Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Segmentation 2: by Route of Administration

• Intravenous
• Oral
• Others

Segmentation 3: by Region

• North America
• Europe
• Asia-Pacific
• Rest of the World

The global Chronic Inflammatory Demyelinating Polyneuropathy market is experiencing significant transformation driven by several emerging trends. There is a growing emphasis on personalized medicine, with advancements in biomarker identification and genomic testing allowing for more targeted and effective treatments for patients with chronic inflammatory demyelinating polyneuropathy. This approach is enabling healthcare providers to tailor therapies to individual patients, improving outcomes and reducing side effects.

Additionally, innovative therapies are reshaping the treatment landscape. For example, FcRn inhibitors like Vyvgart (efgartigimod) from Argenx are offering a new way to treat chronic inflammatory demyelinating polyneuropathy by modulating the immune system to reduce the autoantibodies that attack peripheral nerves. This has opened up new possibilities for patients who do not respond well to traditional intravenous immunoglobulin (IVIG) treatments.

There is also a rise in the use of biologic therapies and immune modulators, which are moving beyond conventional IVIG treatments and targeting the underlying immune processes more specifically. Companies like Biogen and Horizon Therapeutics are developing therapies that offer more targeted, long-term relief for chronic inflammatory demyelinating polyneuropathy patients.

Chronic inflammatory demyelinating polyneuropathy market is also benefiting from improved diagnostic techniques that allow for earlier and more accurate identification of chronic inflammatory demyelinating polyneuropathy. With better awareness and more advanced tools, physicians are able to detect chronic inflammatory demyelinating polyneuropathy earlier, leading to timely interventions that can reduce disease progression and improve patient quality of life.

Finally, increased patient advocacy and awareness campaigns are helping to raise the profile of chronic inflammatory demyelinating polyneuropathy, ensuring that more patients are diagnosed and treated appropriately. These efforts are helping drive demand for new therapies and solutions, accelerating the growth of the chronic inflammatory demyelinating polyneuropathy market.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Chronic Inflammatory Demyelinating Polyneuropathy Market: Industry Outlook

• 1.1 Introduction
• 1.2 Market Trends
• 1.3 Regulatory Framework
• 1.4 Epidemiology Analysis
• 1.5 Clinical Trial Analysis
• 1.6 Market Dynamics
  • 1.6.1 Impact Analysis
  • 1.6.2 Market Drivers
  • 1.6.3 Market Challenges
  • 1.6.4 Market Opportunities

2. Global Chronic Inflammatory Demyelinating Polyneuropathy Market (by Distribution Channel), ($Billion), 2023-2035

• 2.1 Hospital Pharmacy
• 2.2 Retail Pharmacy
• 2.3 Online Pharmacy

3. Global Chronic Inflammatory Demyelinating Polyneuropathy Market (by Route of Administration), ($Billion), 2023-2035

• 3.1 Intravenous
• 3.2 Oral
• 3.3 Others

4. Global Chronic Inflammatory Demyelinating Polyneuropathy Market (Region), ($Billion), 2023-2035

• 4.1 North America
  • 4.1.1 Key Findings
  • 4.1.2 Market Dynamics
  • 4.1.3 Market Sizing and Forecast
    • 4.1.3.1 North America Chronic Inflammatory Demyelinating Polyneuropathy Market, by Country
      • 4.1.3.1.1 U.S.
• 4.2 Europe
  • 4.2.1 Key Findings
  • 4.2.2 Market Dynamics
  • 4.2.3 Market Sizing and Forecast
    • 4.2.3.1 Europe Chronic Inflammatory Demyelinating Polyneuropathy Market, by Country
      • 4.2.3.1.1 Germany
      • 4.2.3.1.2 U.K.
      • 4.2.3.1.3 France
      • 4.2.3.1.4 Italy
• 4.3 Asia Pacific
  • 4.3.1 Key Findings
  • 4.3.2 Market Dynamics
  • 4.3.3 Market Sizing and Forecast
    • 4.3.3.1 Asia Pacific Chronic Inflammatory Demyelinating Polyneuropathy Market, by Country
      • 4.3.3.1.1 China
      • 4.3.3.1.2 Japan
• 4.4 Rest of the World
  • 4.4.1 Key Findings
  • 4.4.2 Market Dynamics
  • 4.4.3 Market Sizing and Forecast

5. Global Chronic Inflammatory Demyelinating Polyneuropathy Market: Competitive Landscape and Company Profiles

• 5.1 Key Strategies and Development
  • 5.1.1 Mergers and Acquisitions
  • 5.1.2 Synergistic Activities
  • 5.1.3 Business Expansions and Funding
  • 5.1.4 Product Launches and Approvals
  • 5.1.5 Other Activities
• 5.2 Company Profiles
  • 5.2.1 Sanofi
    • 5.2.1.1 Overview
    • 5.2.1.2 Top Products / Product Portfolio
    • 5.2.1.3 Top Competitors
    • 5.2.1.4 Target Customers/End-Users
    • 5.2.1.5 Key Personnel
    • 5.2.1.6 Analyst View
  • 5.2.2 Grifols, S.A.
    • 5.2.2.1 Overview
    • 5.2.2.2 Top Products / Product Portfolio
    • 5.2.2.3 Top Competitors
    • 5.2.2.4 Target Customers/End-Users
    • 5.2.2.5 Key Personnel
    • 5.2.2.6 Analyst View
  • 5.2.3 Kedrion Biopharma Inc.
    • 5.2.3.1 Overview
    • 5.2.3.2 Top Products / Product Portfolio
    • 5.2.3.3 Top Competitors
    • 5.2.3.4 Target Customers/End-Users
    • 5.2.3.5 Key Personnel
    • 5.2.3.6 Analyst View
  • 5.2.4 Octapharma AG
    • 5.2.4.1 Overview
    • 5.2.4.2 Top Products / Product Portfolio
    • 5.2.4.3 Top Competitors
    • 5.2.4.4 Target Customers/End-Users
    • 5.2.4.5 Key Personnel
    • 5.2.4.6 Analyst View
  • 5.2.5 AstraZeneca s (Alexion Pharmaceuticals, Inc.)
    • 5.2.5.1 Overview
    • 5.2.5.2 Top Products / Product Portfolio
    • 5.2.5.3 Top Competitors
    • 5.2.5.4 Target Customers/End-Users
    • 5.2.5.5 Key Personnel
    • 5.2.5.6 Analyst View
  • 5.2.6 Argenx SE
    • 5.2.6.1 Overview
    • 5.2.6.2 Top Products / Product Portfolio
    • 5.2.6.3 Top Competitors
    • 5.2.6.4 Target Customers/End-Users
    • 5.2.6.5 Key Personnel
    • 5.2.6.6 Analyst View
  • 5.2.7 Amgen (Horizon Therapeutics plc)
    • 5.2.7.1 Overview
    • 5.2.7.2 Top Products / Product Portfolio
    • 5.2.7.3 Top Competitors
    • 5.2.7.4 Target Customers/End-Users
    • 5.2.7.5 Key Personnel
    • 5.2.7.6 Analyst View
  • 5.2.8 Biogen Inc.
    • 5.2.8.1 Overview
    • 5.2.8.2 Top Products / Product Portfolio
    • 5.2.8.3 Top Competitors
    • 5.2.8.4 Target Customers/End-Users
    • 5.2.8.5 Key Personnel
    • 5.2.8.6 Analyst View
  • 5.2.9 GlaxoSmithKline (Human Genome Sciences, Inc.)
    • 5.2.9.1 Overview
    • 5.2.9.2 Top Products / Product Portfolio
    • 5.2.9.3 Top Competitors
    • 5.2.9.4 Target Customers/End-Users
    • 5.2.9.5 Key Personnel
    • 5.2.9.6 Analyst View
  • 5.2.10 Pfizer Inc.
    • 5.2.10.1 Overview
    • 5.2.10.2 Top Products / Product Portfolio
    • 5.2.10.3 Top Competitors
    • 5.2.10.4 Target Customers/End-Users
    • 5.2.10.5 Key Personnel
    • 5.2.10.6 Analyst View
  • 5.2.11 Takeda Pharmaceutical Company
    • 5.2.11.1 Overview
    • 5.2.11.2 Top Products / Product Portfolio
    • 5.2.11.3 Top Competitors
    • 5.2.11.4 Target Customers/End-Users
    • 5.2.11.5 Key Personnel
    • 5.2.11.6 Analyst View

6. Research Methodology